EVast Bio Inc.
Monday, February 26, 2024
Royale
Multiple Therapeutics
EVast Bio is a US-based, clinical-stage biotech born as a result of ground-breaking work at C4C (https://c4c.cl). EVast Bio is devoted to exploring the vast potential of small Extracellular Vesicles (EVs) as nanotherapeutics and targeted delivery systems, enabling treatments that set new standards in medical innovation.
State
FL
Country
United States
Website
http://www.evast.bio
CEO/Top Company Official
Maximiliano Kunze, MEng
Lead Product in Development
EVA101, an extracellular vesicles-based therapy for osteoarthritis, currently in Phase I-B.
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
One:
EVA201, an extracellular vesicles-based therapy for prostate cancer, currently in preclinical stage.
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}